Patienterne blev behandlet enten med atorvastatin 10 mg dagligt (n=1428) eller placebo (n=1410) i en median opfølgningsperiode på 3, 9 år.
All patients had at least 1 of the following risk factors: hypertension, current smoking, retinopathy, microalbuminuria or macroalbuminuria. Patients were treated with either atorvastatin 10 mg daily (n=1428) or placebo (n=1410) for a median follow-up of 3.9 years.